Improving Outcomes for All Your Patients
NxGen MDx is here to serve you and your patients
NatalCare is NxGen MDx’s philosophy guiding curation of tests for pregnancy planning and reproductive health. Each test is designed to improve pregnancy and newborn outcomes through actionable results and guidance from our medical experts. With NatalCare in mind, we strive to provide every patient with the information they need to plan the best course of action for themselves and their baby.
Carrier Screening
Non-Invasive Prenatal Screening
Hereditary Cancer Panel
Pathogens
Carrier Screening
Carrier Frequency Differs Across Ethnicities
Cystic Fibrosis:
- African American: 1 in 61
- Ashkenazi Jewish: 1 in 29
- Asian: 1 in 88
- Caucasian: 1 in 28
- Hispanic: 1 in 58
- Pan-ethnic: 1 in 45
Spinal Muscular Atrophy:
- African American: 1 in 66
- Ashkenazi Jewish: 1 in 41
- Asian: 1 in 53
- Caucasian: 1 in 35
- Hispanic: 1 in 117
- Pan-ethnic: 1 in 54
Alpha-Thalassemia:
- African American: 1 in 30
- Asian: 1 in 20
- Caucasian: 1 in 500
- Pan-ethnic: 1 in 25
HBB-Related Hemoglobinopathies:
- African American: 1 in 8
- Asian: 1 in 54
- Caucasian: 1 in 373
- Hispanic: 1 in 17
- Mediterranean: 1 in 28
- Pan-ethnic: 1 in 49
At-Risk Couple Rate (ARC) Based on Pan-Ethnic Carrier Frequencies
|
Lab A 274 conditions |
Lab B 114 conditions |
Lab C 108 conditions |
Lab D 176 conditions |
Lab E 150 conditions |
NxGen MDx 145 conditions |
| 1.5% | 1.2% | 1.1% | 1.4% | 1.3% | 11.49% |
- “ACMG recommends all pregnant patients and those planning a pregnancy should be offered Tier 3 ( ≥1/200 carrier frequency;
includes X-linked conditions) screening”1 - “Information about genetic carrier screening should be provided to every pregnant woman”2
- “Carrier screening and counseling ideally should be performed before pregnancy”2
- Our carrier screening includes conditions on the Recommended Uniform Screening Panel (RUSP) to increase actionability and
complement newborn screening (NBS) programs
NxGen MDx Informed Prenatal Screening
Screening For All Pregnancies
- Highly sensitive and specific screening for singleton or twin pregnancies achieved naturally or with ART – regardless of maternal age, ethnicity, or BMI.
The NxGen Informed Prenatal Screen is 81x more likely to yield a result in cases where the patient has a high BMI, as compared to our competitor
WGS vs. SNP Assay Failure Rates
- NxGen MDx (WGS): 0.3%
- Average SNP: 1.4%
- SNP (Twins): 10.6%
- SNP (BMI>30): 24.3%
- Approximately 1/3rd (~33%) of all chromosomal differences fall outside of trisomies 13, 18, 21
- Low no-call rate of 0.3%
Comparing the Features of WGS vs SNP Methodology
| Features | SNP | WGS |
| Common Chromosomal Aneuploidies | ✓ | ✓ |
| Sex Chromosome Aneuploidies | ✓ | ✓ |
| Fetal Sex | ✓ | ✓ |
| Twin Fetal Sex | ✓ | ✓ |
| Microdeletions | ✓ | ✓ |
| Expanded Aneuploidy (23 Chromosomes) Analysis | ✓ | |
| No limitations based on BMI | ✓ | |
| Most Extensive Validation | ✓ | |
| Fewer Unnecessary Invasive Procedures | ✓ |
“ACMG strongly recommends NIPS over traditional screening methods for all pregnant patients with singleton and twin gestations for fetal trisomies 21, 18, and 13 and strongly recommends NIPS”6
22q11.2 Deletion Syndrome
- 22q11.2 deletion syndrome affects approximately 1 in 2,000-4,000 live pregnancies, making it the second most prevalent genetic syndrome after Down Syndrome (T21)7,8
- Over 90% of newly identified patients with 22q11.2 deletion syndrome have de novo deletions – meaning neither parent has the 22q11.2 deletion
Hereditary Cancer Panel
1 in 4 patients seen in OB/GYN clinics meet National Comprehensive Cancer Network (NCCN) guidelines for genetic testing1
The NxGen Hereditary Cancer Tool can incorporate hereditary cancer screening into your patient visits
Click Here for a Demo
- Electronic personal and family history questionnaire
- Provides personalized recommendations for genetic testing following national criteria
Board-certified genetic counselors are available to discuss results and answer questions that providers or patients may have
Pathogen Testing
Accurate results & antibiotic resistance in 24 hours
Vaginosis Panel
Screens for 34 Pathogenic Organisms and ABR
- 50% of new STIs occur in those aged 14-24
- 70% of positive vaginosis cases had more than one pathogen present
- 68% of positive cases had resistance to at least one antibiotic
- 10 million doctor visits per year are due to vaginal infections
- CDC estimates that 1.6 million new gonorrhea infections occur each year, and that half of those infections are resistant to at least one antibiotic
Urinary Tract Infection Testing
Screens for 17 Pathogenic Organisms
- Tests for the majority of community acquired infections
- 30-50% of antibiotic prescriptions are ineffective or used inappropriately
- 42% of positive UTI tests contained 2 or more pathogens
- 82% of positive cases had resistance to at least one antibiotic
STI Positive Cases with Coinfections
Chlamydia |
Gonorrhea |
HSV2 |
Trichomoniasis |
STI: 9%BV: 89%AV: 23% |
STI: 21%BV: 89%AV: 21% |
STI: 8%BV: 75%AV: 38% |
STI: 6%BV: 90%AV: 23% |
90% of positive STI cases also have BV
We assist providers across the nation in ensuring their patients have access to critical women’s healthcare and reproductive testing solutions. Whether your practice specializes in Obstetrics and Gynecology, Maternal Fetal Medicine, IVF, or Family Medicine, NxGen MDx meets you where you’re at and helps integrate our offerings and support seamlessly into your practice’s workflow.
The NxGen MDx Difference
Transparent and informative billing communication
Leading customer service commited to seamlessly integrating with your clinic
Board-certified genetic counselors on hand to guide your patients through their results
Quick Links
Questions?
Sources
- Gregg, A.R., Aarabi, M., Klugman, S. et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 23, 1793–1806 (2021). https://doi.org/10.1038/s41436-021-01203-z
- Carrier screening for genetic conditions. Committee Opinion No. 691.American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;129:e41–55.